Larson Financial Group LLC Cuts Stake in Danaher Co. (NYSE:DHR)

Larson Financial Group LLC cut its holdings in shares of Danaher Co. (NYSE:DHR) by 64.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 881 shares of the conglomerate’s stock after selling 1,595 shares during the quarter. Larson Financial Group LLC’s holdings in Danaher were worth $220,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tsfg LLC boosted its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter worth about $25,000. Cape Investment Advisory Inc. acquired a new position in Danaher during the fourth quarter worth about $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher during the first quarter worth about $30,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $266.19 on Friday. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The firm’s 50 day moving average price is $261.30 and its 200 day moving average price is $255.73. The company has a market cap of $197.16 billion, a P/E ratio of 45.12, a PEG ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm earned $2.05 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DHR. Evercore ISI lowered their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday. Barclays boosted their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.